Table 1: Inhibition of the growth of subcutaneous xenografts of human prostate cancer under the action of RHAMM-targeted peptides. Differences are statistically significant * P <0.05 compared with control tumors (without peptide treatment).
|
A reagent |
Way introductions |
Dose, mg / kg |
Weight Tumors, g |
Tumor inhibition, % |
T / C % |
|
Control group |
subcutaneously |
2,5 |
0,226 |
0,0 |
0,0 |
|
GEGEEGEE |
subcutaneously |
2,5 |
0,091 |
*59,8 |
*40,2 |
|
DFGEEAEE |
subcutaneously |
2,5 |
0,0825 |
*63,5 |
*36,5 |
|
RYQLHPYR |
subcutaneously |
2,5 |
0,0123 |
*94,6 |
*5,4 |